Brandy McKelvy, MD
Pulmonary Disease · Houston, TXNPI 1053344887
Payments from drug & device makers
Across 396 payments — averaging $424.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$137K
- Actelion Pharmaceuticals US, Inc.$11K
- Merck$9K
- La Jolla Pharmaceutical Company$3K
- AbbVie$2K
- Boehringer Ingelheim$1K
- plus $4K from 23 others
What the payments were for
- Consulting fees$4,2903%
- Speaking & faculty fees$132,93179%
- Travel & lodging$13,6798%
- Food & beverage$17,00910%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 203 | $137,298 |
| Actelion Pharmaceuticals US, Inc. | 45 | $11,331 |
| Merck | 27 | $9,500 |
| La Jolla Pharmaceutical Company | 11 | $3,019 |
| AbbVie(2 entities) | 29 | $1,693 |
| Boehringer Ingelheim | 30 | $1,050 |
| AstraZeneca(2 entities) | 9 | $942 |
| Mallinckrodt Hospital Products Inc. | 3 | $397 |
| Amgen(2 entities) | 3 | $321 |
| Sandoz | 6 | $285 |
| Bayer | 4 | $250 |
| Sanofi | 4 | $231 |
| Jazz Pharmaceuticals Inc. | 2 | $195 |
| Inspire Medical Systems, Inc. | 3 | $179 |
| Portola Pharmaceuticals, LLC | 1 | $132 |
| Fisher & Paykel Healthcare Inc | 1 | $125 |
| Shionogi Inc | 1 | $125 |
| Sobi, Inc | 1 | $125 |
| Alcresta Therapeutics, Inc. | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $102 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $92 |
| Vapotherm Inc | 1 | $86 |
| Smith+Nephew | 1 | $84 |
| BTG International Inc. | 1 | $77 |
| Johnson & Johnson | 2 | $69 |
| Tactile Systems Technology Inc | 1 | $47 |
| Insmed, Inc. | 2 | $41 |
| Fresenius USA Marketing, Inc. | 1 | $36 |
| Inogen, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$167,968 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 61 | $763,964 |
| Orenitram ErTreprostinil Diolamine | 49 | $743,440 |
| AdempasRiociguat | 20 | $264,615 |
| Tadalafil | 47 | $52,243 |
| Ambrisentan | 12 | $14,956 |
| Sildenafil Citrate | 18 | $9,631 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $7,977 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,964 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $6,070 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,715 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,438 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,680 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,634 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $11,331 | $763,96461 claims |
| BayerAdempas | $250 | $264,61520 claims |
| Boehringer IngelheimCombivent Respimat, Stiolto Respimat | $1,050 | $14,86929 claims |
| AstraZenecaSymbicort | $942 | $2,68011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.